Radiotracers for positron emission tomography imaging**
References (219)
- et al.
PET radiopharmaceuticals: State-of-the-art and future prospects
- et al.
Automated production of several positron-emitting radiopharmaceuticals using a single laboratory robot
Appl Radiat Isot
(1988) - et al.
Report of an International Atomic Energy Agency's Advisory Group meeting on “Quality control of cyclotron-produced radiopharmaceuticals”
- et al.
[18F]Fluoro-l-dopa for the in vivo study of intracerebral dopamine
Int J Rad Appl Instrum A
(1986) New insights into a pathophysiology of Parkinson's disease: The challenge of positron emission tomography
Trends Neurosci
(1988)- et al.
3-(2′-[18F]Fluoroethyl)spiperone, a potent dopamine antagonist: Synthesis, structural analysis and in-vivo utilization in humans
Appl Radiat Isot
(1990) - et al.
Assays for noninvasive imaging of reporter gene expression
Nucl Med Biol
(1999) - et al.
Synthesis and evaluation of high affinity aryl substituted [18F]fluoropropylbenzamides for dopamine D2 receptor studies
Nucl Med Biol
(1992) - et al.
Radiosynthesis and in vitro evaluation of 2-(N-alkyl-N-1-11C-propyl)amino-5-hydroxytetralin analogs as high affinity agonists for dopamine D2 receptors
Nucl Med Biol
(1999) - et al.
(−)-N-[11C]Propyl-norapomorphine: A positron-labeled dopamine agonist for PET imaging of D2 receptors
Nucl Med Biol
(2000)
Synthesis and autoradiographic localization of the dopamine D-1 agonists [11C]SKF 75670 and [11]SKF 82957 as potential PET radioligands
Appl Radiat Isot
(1996)
Carbon-11 PB-12: An attempt to visualize the dopamine D4 receptor in the primate brain with positron emission tomography
Nucl Med Biol
(2000)
Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs
Pharmacol Ther
(2001)
[11C]Cocaine: PET studies of cocaine pharmacokinetics, dopamine transporter availability and dopamine transporter occupancy
Nucl Med Biol
(2001)
In vivo tracers for vesicular neurotransmitter transporters
Nucl Med Biol
(1997)
Synthesis of some 11C-labeled MAO A inhibitors and their in vivo uptake kinetics
Nucl Med Biol
(1997)
Ligands and tracers for PET studies of the 5-HT system—Current status
Nucl Med Biol
(1992)
Radioligands for PET studies of central 5-HT receptors and re-uptake sites—Current status
Nucl Med Biol
(1995)
A review of central 5-HT receptors and their function
Neuropharmacology
(1999)
[11C]WAY 100635: A radiologand for imaging 5-HT1A receptors with positron emission tomography
Life Sci
(1994)
[18F]p-MPPF: A radiolabeled antagonist for the study of 5HT1A receptors with PET
Nucl Med Biol
(2000)
[11C](+)McN5652 as a radiotracer for imaging serotonin uptake sites with PET
Life Sci
(1993)
PET imaging of the opioid receptor: The early years
Nucl Med Biol
(2001)
Positron emitter-labeled compounds: Priorities and problems
Fluorine-18 Labeling of Radiopharmaceuticals
Working against time. Rapid radiotracer synthesis and imaging the human brain
Accts Chem Res
(1997)
Compounds labelled with short-lived beta(+)-emitting radionuclides and some applications in life sciences. The importance of time as a parameter
Acta Chem Scand
(1999)
Electronic generators for the production of positron-emitter labeled radiopharmaceuticals: Where would PET be without them?
Clin Positron Imaging
(1999)
Knowledge-based automated radiopharmaceutical manufacturing for positron emission tomography
Neurochemical systems in the central nervous system
PET evaluation of the dopamine system of the human brain
J Nucl Med
(1996)
Dopamine visualized in the basal ganglia in living man
Nature
(1983)
Cerebral metabolism of 6-18F-fluoro-l-3,4-dihydroxy-phenylalanine in the primate
J Neurochem
(1987)
Evaluation of fluorinated m-tyrosine analogs as PET imaging agents of dopamine nerve terminals: Comparison with 6-fluoroDOPA
J Nucl Med
(1997)
Enzymatic synthesis of carboxy-11C-labeled l-tyrosine, l-DOPA, l-tryptophan and 5-hydroxy-l-tryptophan
Acta Chem Scand
(1990)
Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs
Arch Gen Psychiatry
(1988)
N-(3-[18F]fluoropropyl)-Spiperone: The preferred 18F labeled spiperone analog for PET studies of the dopamine receptor
Nucl Med Biol
(1998)
Effects of endogenous dopamine on measures of [18F]N-methylspiroperidol binding in the basal ganglia: Comparison of simulations and experimental results from PET studies in baboons
Synapse
(1991)
Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography
USP standards for raclopride C 11 injection
Pharmacopeial Forum
(1995)
Striatal binding of the PET ligand 11C-raclopride is altered by drugs that modify synaptic dopamine levels
Synapse
(1993)
Imaging endogenous dopamine competition with [11C]raclopride in the human brain
Synapse
(1994)
Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects
Nature
(1997)
Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method
Imaging synaptic neurotransmission with in vivo binding competition techniques: A critical review
J Cereb Blood Flow Metab
(2000)
Expectation and dopamine release: Mechanism of the placebo effect in Parkinson's disease
Science
(2001)
Comparison of two fluorine-18 labeled benzamide derivatives that bind reversibly to dopamine D2 receptors: In vitro binding studies and positron emission tomography
Synapse
(1996)
Quantitation of striatal and extrastriatal D-2 dopamine receptors using PET imaging of [18F]fallypride in nonhuman primates
Synapse
(2000)
Evaluation of 5-[18F]fluoropropylepidepride as a potential PET radioligand for imaging dopamine D2 receptors
Synapse
(1993)
Cited by (0)
- **
Much of this work was performed at Brookhaven National Laboratory under Contract DE-AC02-98CH10886 with the US Department of Energy and was supported by its Office of Biological and Environmental Research and the National Institutes of Health (National Institutes of Neurological Diseases and Stroke Grant NS15380).
Copyright © 2003 Published by Elsevier Inc.